Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Impact of Spleen Preservation in Patients with Gastric Cancer

MICHAEL FATOUROS, DIMITRIOS H. ROUKOS, MATTHIAS LORENZ, IOANNIS ARAMPATZIS, CHRISTOF HOTTENTROTT, ALBRECHT ENCKE and ANGELOS M. KAPPAS
Anticancer Research July 2005, 25 (4) 3023-3030;
MICHAEL FATOUROS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIMITRIOS H. ROUKOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: droukos@cc.uoi.gr
MATTHIAS LORENZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IOANNIS ARAMPATZIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTOF HOTTENTROTT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALBRECHT ENCKE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELOS M. KAPPAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Resection of the spleen en bloc with the stomach for gastric cancer is still widely performed for a curative resection (R0), but the presence of the spleen may have a favorable effect on recurrence control and survival. The hypothesis that the spleen suppresses tumor growth from minimal residual disease in the critical early postsurgical period and reduces the risk of recurrent disease was tested. Patients and Methods: Patients were included who underwent gastrectomy, with or without splenectomy, for gastric adenocarcinoma. Standardized, strongly-defined criteria were used to accurately stratify patients, who had an extended (D2) lymph node dissection, into the curative and non-curative resection groups. Limited, D1 resection confounds appropriate R-stratification and thus D1 patients were excluded. Prospectively-defined primary endpoints were early (within two years) and overall recurrence and death from any cause and secondary endpoints were postsurgical risks (morbidity, mortality) and metastases to the splenic hilum nodes. Results: Overall survival for the total population studied (n=202) was better for preservation-versus-resection of the spleen among R0 patients (p=0.0001), but not for those with non-curative resection (p=0.42). For the R0 D2 group of patients, preservation (n=59) over resection (n=67) of the spleen, there was no significant difference in in-hospital postoperative morbidity or mortality (3.4% vs. 0%). At a median follow-up of 112 months, significantly the preservation of the spleen, lowered the risks of early recurrence (HR, 0.33; 95% CI, 0.16 to 0.69; p=0.003) and death from any cause (p=0.009) after adjustment analysis. Since at baseline there was a significant imbalance of tumor stage in favor of the spleen-preservation group, we conducted a stage-stratified subgroup analysis. This treatment effect remained consistent in the subgroup analyses according to nodal and serosal status, while in multivariate analysis preservation of the spleen was an independent predictor of outcome. An overestimation of the risk for residual disease in the splenic hilum nodes in the case of spleen preservation was obtained in 94% of splenectomized patients. Conclusion: Our findings indicate that preservation of the spleen may be associated with a reduced risk of early and overall recurrence translated into a better survival in patients receiving curative surgery for gastric cancer. A large randomized trial is needed to confirm this finding. Indications for splenectomy are few, being limited to those patients with advanced proximal cancers.

  • Gastric cancer
  • gastrectomy with spleen preservation / splenectomy
  • recurrence
  • survival

Footnotes

  • Received November 2, 2004.
  • Revision received May 27, 2005.
  • Accepted June 1, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Spleen Preservation in Patients with Gastric Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Impact of Spleen Preservation in Patients with Gastric Cancer
MICHAEL FATOUROS, DIMITRIOS H. ROUKOS, MATTHIAS LORENZ, IOANNIS ARAMPATZIS, CHRISTOF HOTTENTROTT, ALBRECHT ENCKE, ANGELOS M. KAPPAS
Anticancer Research Jul 2005, 25 (4) 3023-3030;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Impact of Spleen Preservation in Patients with Gastric Cancer
MICHAEL FATOUROS, DIMITRIOS H. ROUKOS, MATTHIAS LORENZ, IOANNIS ARAMPATZIS, CHRISTOF HOTTENTROTT, ALBRECHT ENCKE, ANGELOS M. KAPPAS
Anticancer Research Jul 2005, 25 (4) 3023-3030;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Limited Oncological Benefits of Laparoscopic Total Gastrectomy With Splenectomy for Patients With Type 4 or Large Type 3 Gastric Cancer
  • Systemic Review and Meta-analysis of Impact of Splenectomy for Advanced Gastric Cancer
  • Oncologic Effectiveness and Safety of Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Meta-analysis of Randomized Controlled Trials
  • Frequency of Lymph Node Metastasis to the Splenic Hilus and Effect of Splenectomy in Proximal Gastric Cancer
  • Modern Surgical Considerations for Gastric Cancer
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire